Shares of Regenxbio Inc. (NASDAQ:RGNX) shot up 7% during trading on Monday . The company traded as high as $9.36 and last traded at $9.30, with a volume of 64,722 shares traded. The stock had previously closed at $8.69.

A number of brokerages recently commented on RGNX. Zacks Investment Research upgraded Regenxbio from a “sell” rating to a “hold” rating in a research report on Thursday, April 14th. Piper Jaffray Cos. reiterated a “buy” rating and issued a $33.00 price objective on shares of Regenxbio in a research report on Tuesday, July 5th. Finally, Chardan Capital restated a “buy” rating on shares of Regenxbio in a research report on Tuesday, May 10th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $28.35.

The stock has a 50-day moving average of $8.24 and a 200-day moving average of $11.00. The company’s market capitalization is $249.68 million.

Regenxbio (NASDAQ:RGNX) last announced its quarterly earnings data on Thursday, May 5th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.40) by $0.01. Equities research analysts predict that Regenxbio Inc. will post ($2.37) earnings per share for the current fiscal year.

In other Regenxbio news, insider Fmr Llc sold 6,711 shares of the stock in a transaction dated Thursday, May 12th. The stock was sold at an average price of $10.85, for a total value of $72,814.35. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

A hedge fund recently raised its stake in Regenxbio stock. RS Investment Management Co. LLC raised its stake in Regenxbio Inc. (NASDAQ:RGNX) by 11.3% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 746,592 shares of the company’s stock after buying an additional 75,810 shares during the period. RS Investment Management Co. LLC owned 2.84% of Regenxbio worth $12,393,000 as of its most recent SEC filing.

REGENXBIO Inc is a biotechnology company. The Company is focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. Its AAV gene delivery platform (its NAV Technology Platform) consists of rights to over 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10 (NAV Vectors).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.